
# ClinicalTrials.gov Modernization and How to Provide Your Input

Rebecca J. Williams, Acting Director, ClinicalTrials.gov January 22, 2020


## Agenda

- ClinicalTrials.gov Background
- Modernization Overview
- Request for Information (RFI)
- Provide Your Input



### Overview

- 320,000+ registrations
- 40,000+ posted results
- 145,000 unique visitors daily
- 215 million page views per month



# Benefits of Comprehensive Registration and Results Reporting


All contribute to increased public trust in clinical research

- Honor commitment to participants that their contributions will advance science; support enrollment
- Mitigate publication bias
- Advance stewardship and accountability
  - Identify unmet research needs
  - Facilitate complete reporting
  - Avoid unnecessary study duplication
  - Evaluate research integrity
- Support evidence-based medicine

# ClinicalTrials.gov Modernization

Ensure ClinicalTrials.gov continues to be a trusted and valued premier public health resource that provides maximum value to the public and serves its mission well into the future.


# Aim 1: Collect complete and informative information about clinical studies




See Submit Studies on ClinicalTrials.gov for information on how to apply for an account, how to register your study,

Send email to ClinicalTrials.gov PRS Administration


# Aim 2: Facilitate use of information to help the public and researchers find studies of interest



ClinicalTrials.gov API



# ClinicalTrials.gov: Information Scaffold



## ClinicalTrials.gov Key Roles and Principles


- Sponsor or investigator
  - Submits study information directly to ClinicalTrials.gov; keeps up-to-date
  - Responsible for safety and validity of study and following applicable laws and regulations
- NLM conducts a limited quality control (QC) review
  - Identifying apparent errors, deficiencies, or inconsistencies
  - Listing does not mean study itself has been evaluated by U.S. government
- Site lists information for many uses, including research participation
  - Participation is an important personal decision; encourage learning about all options and consulting with health care provider and other trusted advisors

**Source:** Disclaimer <a href="https://clinicaltrials.gov/ct2/about-site/disclaimer">https://clinicaltrials.gov/ct2/about-site/disclaimer</a>



## ClinicalTrials.gov Modernization Overview

### Clinical Research Life Cycle



#### **Current year: Engagement**

- Engage with stakeholders to determine and validate approach and specifications
  - · Request for Information (RFI) and Public Meeting
- Develop modernization roadmap
- Enhance internal business processes

#### Future (years 2 – 5): Implementation

- Implement modernization roadmap
  - User testing/evaluation and continue engagement
  - Improvements to support compatibility across clinical trial lifecycle (seamless end-to-end process)
  - Upgrade system infrastructure components

#### Request for Information (RFI): ClinicalTrials.gov

#### Modernization

**Notice Number:** 

NOT-LM-20-003

#### **Key Dates**

Release Date:

December 30, 2019

Response Date:

March 14, 2020

#### Related Announcements

None

#### Issued by

National Library of Medicine (NLM)

#### Purpose

#### Introduction

The purpose of this Request for Information is to solicit public input to guide the National Library of Medicine (NLM) in planning infrastructure enhancements aimed at users and submitters of ClinicalTrials.gov as part of a multi-year modernization initiative.

### Request for Information (RFI)

• "... we aim to gather information to help maximize the value of ClinicalTrials.gov to its many users, while continuing to provide essential services to support existing legal and policy requirements."

March 14 – responses due

# We Request Your Input on These Topics

- Website functionality
- 2 Information submission
- 3 Data standards

<u>Note</u>: RFI not intended to modify existing legal and policy requirements for clinical trial registration and results submission

## 1. Provide Your Input: Website Functionality

- a. Uses that are not currently supported and examples of other good models
- b. Resources that should be linked from ClinicalTrials.gov and explanation of why such resources are useful
- Examples of how you currently use site, what features work well, and what could be improved
- d. Describe whether uses are dependent on wide range of studies or more limited and explain any limiting criteria that are useful to you

# ClinicalTrials.gov Users by Role

# 42% Patients and Caregivers, including:

- 24% Patient
- 8% Family/friend of patient
- 5% Healthcare provider
- 5% Healthy person

9% Not Categorized ("Other")

# 49% Researchers and Others, including:


- 26% Scientist/researcher
- 8% Clinical research support (e.g., regulatory affairs)
- 6% Clinical trials staff
- 5% Student/educator
- 3% Medical communications
- 2% Librarian or information professional
- <1% IRB or ethics committee member

Source: ClinicalTrials.gov Qualtrics Survey Data: 1 July 2019 – 31 December 2019 (n=3,399)



# Recent Website Updates

- Options to improve first search precision
  - A. Recruitment status
  - B. Location
- Research participation resources and disclaimer
  - Help people learn what ClinicalTrials.gov listing does and doesn't mean
- Search results options;
   filters and custom display



# Beta API (Application Programming Interface)

- Supports 3<sup>rd</sup> party electronic use of ClinicalTrials.gov content
- Over 300 search fields available (current API has 24 key fields)
- Formats: XML, JSON, SVI, tree
- Query and Info URLs
- Documentation and interactive training demos
- https://clinicaltrials.gov/api/gui



#### **API Home (BETA)**

The ClinicalTrials.gov BETA application programming interface (API) is being made available for beta testing and feedback. After further development, it is intended to replace the <u>current API</u>.

If you are looking for information about clinical studies, please visit ClinicalTrials.gov

#### ClinicalTrials.gov main site

The ClinicalTrials.gov application programming interface (API) provides a toolbox for programmers and other technical users to use to access all posted information on ClinicalTrials.gov study records data. The API is designed for encoding simple and complex search expressions and parameters in URLs. Clicking on query URLs retrieves study records from ClinicalTrials.gov. Use of ClinicalTrials.gov data is subject to these Terms and Conditions.

If you are looking for information about clinical studies, please visit Clinical Trials.gov.

#### Documentation

Use the following links to learn about the ClinicalTrials.gov API.		
Link	Description	
APIURLs	List of info URLs for accessing information about the API and query URLs with parameters.	
Query URL Responses	Description of information returned by query URLs.	

#### Interactive Demonstrations

Use the following demonstrations to explore and develop the three types of query URLs available for accessing different levels of API data from ClinicalTrials.gov.

Query URL Type	Description	Example	
Full Studies	Retrieves all content from the first study record returned for a submitted query by default. Returns up to 100 study records per query when the minimum rank and maximum rank parameters are set in a query URL and up to 100,000 records using the Full Studies interactive demonstration.	https://ClinicalTrials.gov/api/query /full_studies?expr=heart+attack	
Study Fields	Retrieves the values of one or more fields from up to 100,000 study records returned for a submitted query by default. Returns up to 1,000 study records per query when the minimum rank and maximum rank parameters are set in a query URL and up to 100,000 records using the Study Fields interactive demonstration.	https://ClinicalTrials.gov/api/query /study_fields?expr=heart+attack& fields=NCTId,Condition,BriefTitle	
ield Values	Retrieves a unique list of values for one study field from all study records returned for a submitted query.	https://ClinicalTrials.gov/api/query /field_values?expr=heart+attack& field=Condition	

CURRENT API VERSION 1.01.01 REPORT PROBLEM

Copyright | Privacy | Accessibility | Freedom of Information Act | USA.gov

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health and Human Serv



# Content of ClinicalTrials.gov (as of Jan 10, 2020)

Study and Intervention Type		Number Registered Studies (% Total)	No. Studies with Posted Results (% Total) ***	
Total Records		326,612	40,841	
Interventional Studies		257,482 (79%)	38,361 (94%)	
Type of Intervention*	Drug or biologic	144,503	29,807	
	Behavioral, other	83,013	7,279	
	Surgical procedure	27,089	2,068	
	Device**	32,977	5,063	
<b>Observational Studies</b>		67,671 (21%)	2,480 (6%)	
<b>Expanded Access</b>		603	N/A	

<sup>\*</sup>A study may include more than one type of intervention, meaning that a single study may be counted more than once.


Source: ClinicalTrials.gov Trends, Charts, Maps (Jan 10, 2020) <a href="https://clinicaltrials.gov/ct2/resources/trends">https://clinicaltrials.gov/ct2/resources/trends</a>



<sup>\*\*</sup>A total of 856 applicable device clinical trials have been submitted as "delayed posting" under FDAAA/Part 11 (i.e., in "lockbox") and are not included in the counts of trials.

<sup>\*\*\*</sup>Results are required to be submitted only for certain studies.

## Location of Registered Studies (as of Jan 10, 2020)



Location of Study Sites	Number Registered Studies (% Total)
United States (U.S.) only	110,661 (34%)
Both U.S. and non-U.S.	17,051 (5%)
Non-U.S. Only	160,085 (49%)
Not provided	38,815 (12%)
Total	326,612 (100%)

Source: ClinicalTrials.gov Trends, Charts, Maps (Jan 10, 2020) <a href="https://clinicaltrials.gov/ct2/resources/trends">https://clinicaltrials.gov/ct2/resources/trends</a>



## 2. Provide Your Input: Information Submission


- Steps in submission process that would most benefit from improvements
- b. Opportunities for alignment with organization processes, such as interoperability with clinical trial management software or tools
- c. Novel or emerging methods for enhancing quality and submitted content and displayed on ClinicalTrials.gov
- d. Informational materials that would make process easier
- e. Ways to credit, incentivize, or recognize efforts of individuals and organizations submitting complete, accurate, and timely information

### Basics of Registration Information Submission

### ClinicalTrials.gov PRS

Protocol Registration and Results System

- Interactive data entry or automated upload
- Anyone can enter data, but "responsible party" must submit
- Content reflects:
  - Legal requirements
  - International standards
  - Good reporting practices
- NIH grant application aligns with subset of content




### Basics of Results Information Submission

### ClinicalTrials.gov PRS

Protocol Registration and Results System

- Structure supports:
  - Complete reporting
  - Efficient quality review
  - Consistent data display
  - Detailed search and integration of other NLM resources
- Aligns with good reporting practices (CONSORT)

#### **Edit Baseline Measure**





## Quality Control Review Process and Volume

- Quality control review focused on identifying apparent errors, deficiencies, or inconsistencies
- Review all registration study records < 5 days</li>
  - ~1,200 new registration records per week (includes new records and previously reviewed records that did not meet QC review criteria)
  - ~6,600 updated registration records per week
- Review all results study records < 25 days</li>
  - ~280 new results records per week (includes new records and previously reviewed records that did not meet QC review criteria)
  - ~140 updated results records per week

# Quality Control Review Example

#### **Baseline Measures – Example**

	Drug X
<b>GOG Performance Status</b>	
[units: participants]	
0	48
1	27
2	4

#### **Baseline Measures – Example Corrected**

	Drug X
Gynecological Oncology Group (GOG) Performance Status	
[units: participants]	
0 – Fully Active	48
1 – Restricted Strenuous Activity, Ambulatory	27
2 – Ambulatory, Difficulty Walking	4
3 – Limited Self-Care, Partly Confined to Bed	0
4 – Completely Disabled, No Self-Care	0

5-point, ordinal scale specifying patient's ability to perform activities from 0 (fully active) to 4 (completely disabled, no self-care)

# Results Submission "Success:" Industry and Non-Industry Orgs

<u>Sample</u>: initial results submitted ≥ 1 May 2017 and QC reviewed ≤ 30 Sept 2018

		Cycle 1		Сус	ele 2
Org Type	# Orgs	#Records	% Success	#Records	% Success
Industry	572	2780	31	2140	77
Non- Industry	777	3486	17	2359	63
All	1349	6266	23	4499	70


**Source:** N Engl J Med 2019; 381:1966-74. DOI: 10.1056/NEJMsr1907644

 $\%Success = 100\% \times \frac{\# Records \ with \ no \ Major \ Issues}{\# Total \ Record \ Submissions}$ 




### PRS Guided Tutorials

- Launched August 2019
- Access on ClinicalTrials.gov or PRS
- Results submission content first
  - Registration content expected in early 2020
- Collecting feedback via survey
  - https://bit.ly/2N1mMHV
  - Further evaluation planned



this information is translated is shown here in the CONSORT Flow Diagram to Participant Flow Table Crosswalk.

#### **CONSORT Diagram to Participant Flow Table Crosswalk**



#### Resources

Before entering information in the Participant Flow module, use these resources to help you gather and organize the information you will need:


- Participant Flow Data Preparation Checklist
- Participant Flow Template
- Results Data Element Definitions—Participant Flow

You can also refer to the Results Quality Control Review Criteria, which will help you

## 3. Provide Your Input: Data Standards

- a. Input on ways to balance use of standards while also retaining flexibility to accurately reflect content of study protocol and statistical analysis plan
- b. Name specific standards and explain how they may be useful in improving data quality, enabling reuse of data to reduce reporting burden, or improving consistency and management of data on ClinicalTrials.gov

### Clinical Trial Lifecycle Opportunities



**National Library of Medicine** 

Clinical Trial Milestones

# Submitting Feedback

- "The Insider's Guide to Effective Commenting on NIH Policies" (from the NIH Office of Science Policy)
  - Be specific
  - Provide data
  - Answer the questions
  - Include new ideas
  - Emphasize what matters most
- Reference: <a href="https://osp.od.nih.gov/2018/06/08/insides-guide-effective-commenting-nih-policies/">https://osp.od.nih.gov/2018/06/08/insides-guide-effective-commenting-nih-policies/</a>

## Submitting Feedback - Reminders

- March 14, 2020 is the deadline for submitting feedback using webbased form accessible from the RFI:
  - https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-003.html
- Submitted responses will be posted publicly without change after the close of the comment period.
  - Do not include proprietary, classified, confidential, or sensitive information
  - Do not include personally identifiable information you do not wish to be made public
- RFI not intended to modify existing legal and policy requirements for clinical trial registration and results submission

## Public Meeting – April 30, 2020

- We will share a summary of the RFI responses and initial interpretation of themes and priorities
- Opportunity for further discussion and clarification of topics
- More details on how to register will be available soon
  - Hosted at the NIH in Bethesda, MD and also available by Webcast

# Stay up to date with Hot Off the PRS!

- E-mail bulletin
- Provides timely updates for PRS users on new information about the PRS and ClinicalTrials.gov
- Sign up: <a href="https://bit.ly/33qcZBb">https://bit.ly/33qcZBb</a>



#### **Hot Off the PRS!**

Latest Release and Updates





Having trouble viewing this email? View it as a Web page.





#### Welcome to Hot Off the PRS!

We are excited to share the first *Hot Off the PRS!* bulletin. We are planning to use the bulletin to provide timely announcements about the Protocol Registration and Results System (PRS), including updates on new features planned for the PRS, 42 CFR Part 11 implementation, and resources for PRS users. We will still continue to post announcements of new features and resources when they are available in the What's New on ClinicalTrials.gov and in the PRS. We hope you find *Hot Off the PRS!* to be a valuable resource for staying informed.

Note: This bulletin replaced the NIH FDAAA Update listserv on Aug. 1, 2019.



#### Parallel Study Design Example Has Been Updated

The Example Studies for Results Data Entry are example study records and study papers that are useful for understanding key concepts for results data entry in the PRS. The Parallel Study Design example has been updated for consistency with the data elements and content in the Final Rule for Clinical Trials Registration and Results Information Submission (42 CFR Part 11). The example also now reflects the current display of study results information on Clinical Trials gay. More undates for those example

## **Thank You**

# Questions? Submit to the ClinicalTrials.gov Information Team National Library of Medicine

register@clinicaltrials.gov

**ClinicalTrials.gov Modernization Information** 

https://clinicaltrials.gov/ct2/about-site/modernization

A recording of this presentation will be posted within 7 days.